(18.204.227.34)
Users online: 2180    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacognosy and Phytochemistry
Year : 2017, Volume : 9, Issue : 3
First page : ( 173) Last page : ( 176)
Print ISSN : 0975-2331. Online ISSN : 0975-4385.
Article DOI : 10.5958/0975-4385.2017.00032.2

Identification of New Inhibitor against Mycobacterium tuberculosis using Structure Based Drug Designing and Docking Studies

Sivakumar Subramaniam*, Sangeetha D

Department of Biochemistry, Sri Sankara Arts and Science College (Autonomous), Enathur-631 561.

*Corresponding Author E-mail: sivabio@gmail.com

Online published on 17 October, 2017.

Abstract

Bioinformatics is playing a vital role in all aspects of drug discovery, drug assessment and drug development. It is intensively utilized for the development new drugs against several dreadful diseases. Mycobacterium tuberculosis is the etiologic agent of tuberculosis in humans. This disease affects 1.8 billion people per year which is equal to one-third of the entire population of world. To eradicate the tuberculosis the following steps are followed, target and drug for the Mycobacterium tuberculosis identified from drug bank, homology modelling prediction carried out for the prediction of tertiary structure of fatty acyl CoA synthetase by using CPH Model server, similar chemical compounds to drug were retrieved from PubChem database, docking of enzyme with ligands achieved, molecular property using molinspiration online tool was calculated and the best ligand was finally selected as 2-pyrazinoylguanidine.

Top

Keywords

Mycobacterium tuberculosis, drug discovery, pyrazinamide, fatty acyl CoA synthetase, docking, drug resistance.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
490,484,085 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.